{
    "guideline": {
        "id": "PA166104987",
        "name": "Annotation of DPWG Guideline for lansoprazole and CYP2C19",
        "source": "DPWG",
        "version": 30,
        "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104987",
        "relatedChemicals": [
            {
                "id": "PA450180",
                "name": "lansoprazole",
                "symbol": null
            }
        ],
        "relatedGenes": [
            {
                "id": "PA124",
                "name": "cytochrome P450 family 2 subfamily C member 19",
                "symbol": "CYP2C19"
            }
        ],
        "recommendation": true
    },
    "recommendations": [
        {
            "id": "PA166299062",
            "name": "Recommendation PA166299062",
            "population": null,
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA450180",
                    "name": "lansoprazole",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452061425,
                "html": "<p>The guideline does not provide a recommendation for lansoprazole in normal metabolizers.</p>\n"
            },
            "implications": [
                "The guideline does not provide a description of the impact of a normal metabolizer phenotype on lansoprazole."
            ],
            "lookupKey": {
                "CYP2C19": "Normal Metabolizer"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166299061",
            "name": "Recommendation PA166299061",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA450180",
                    "name": "lansoprazole",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452061424,
                "html": "<p>NO action is needed for this gene-drug interaction.</p>\n"
            },
            "implications": [
                "The higher plasma concentration of lansoprazole results in an increase in the therapeutic effectiveness, without an increase in the incidence of side effects."
            ],
            "lookupKey": {
                "CYP2C19": "Intermediate Metabolizer"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166299060",
            "name": "Recommendation PA166299060",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA450180",
                    "name": "lansoprazole",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452061423,
                "html": "<p>NO action is needed for this gene-drug interaction.</p>\n"
            },
            "implications": [
                "The higher plasma concentration of lansoprazole results in an increase in the therapeutic effectiveness, without an increase in the incidence of side effects."
            ],
            "lookupKey": {
                "CYP2C19": "Poor Metabolizer"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166299063",
            "name": "Recommendation PA166299063",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA450180",
                    "name": "lansoprazole",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452061426,
                "html": "<p>For Helicobacter pylori ERADICATION THERAPY: 1. Use a 4-fold higher dose. 2. Advise the patient to contact their doctor if symptoms of dyspepsia persist.\nOTHER INDICATIONS: 1. Be alert to reduced effectiveness. 2. If necessary, use a 4-fold higher dose. 3. Advise the patient to report persisting symptoms of dyspepsia.</p>\n"
            },
            "implications": [
                "The genetic variation may reduce lansoprazole plasma concentrations and therefore lansoprazole effectiveness."
            ],
            "lookupKey": {
                "CYP2C19": "Ultrarapid Metabolizer"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "2"
        }
    ],
    "citations": [
        {
            "pmid": "21412232",
            "title": "Pharmacogenetics: from bench to byte--an update of guidelines.",
            "authors": [
                "Swen J J",
                "Nijenhuis M",
                "de Boer A",
                "Grandia L",
                "Maitland-van der Zee A H",
                "Mulder H",
                "Rongen G A P J M",
                "van Schaik R H N",
                "Schalekamp T",
                "Touw D J",
                "van der Weide J",
                "Wilffert B",
                "Deneer V H M",
                "Guchelaar H-J"
            ],
            "journal": "Clinical pharmacology and therapeutics",
            "year": 2011
        }
    ],
    "version": "2024-03-25-16-13"
}